Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2008

Scientists Found Biomarker for Prostate Cancer Recurrence

  • Oregon Health & Science University Cancer Institute researchers report that silencing the gene CDH13 is predictive of prostate cancer recurrence.

    While this gene is active tn normal cells,  in some cancer cells, it may be turned off, which leads to a propensity for metastasis, according to the OHSU team.

    In the study, the researchers looked at tissue samples from 151 subjects with localized prostate cancer with at least five years of follow-up after their prostatectomies. They observed that two-third of the subjects were free of recurrence.

    The investigators found that men whose tumors showed a silencing of CDH13 had a fivefold increased risk of prostate cancer recurrence compared to men whose tumors showed no silencing of this gene.

    The research will be presented at the “2008 American Society of Clinical Oncology Genitourinary Symposium.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »